COST COMPARISON OF RFVIIA AND PLASMA-DERIVED FACTOR VII FOR BLEEDING MANAGEMENT IN COLOMBIA
Author(s)
Alexander Moreno-Calderón, PhD1, DAYSI J. SANMARTIN DURANGO, MSc2, Juan Sebastian J. Salazar, Econ2, María A. Barrios-Mercado, MSc, MD2, Leydy Pineda-Cubillos, MD1, Claudia Cortés-Ibarra, MSc1, Maria Nieto-Rojas, MD, MSc1;
1Novo Nordisk, Bogotá, Colombia, 2Sapyens SAS BIC, Bogotá, Colombia
1Novo Nordisk, Bogotá, Colombia, 2Sapyens SAS BIC, Bogotá, Colombia
Presentation Documents
OBJECTIVES: Management of acute bleeding events requires use of procoagulant therapies that are associated with substantial pharmaceutical costs. In Colombia, recombinant activated factor VII (rFVIIa) and plasma-derived factor VII concentrate (pd-FVII) are therapeutic options used across different bleeding severities and surgical settings. Comparative cost evidence across clinically relevant scenarios is needed to support efficient resource allocation within the health system. The aim of this study was to compare pharmacological treatment costs of rFVIIa and pd-FVII for the management of bleeding events and surgical procedures in Colombia, from a third-party payer perspective.
METHODS: A cost comparison analysis was conducted following methodological recommendations of the Instituto de Evaluación Tecnológica en Salud (IETS). Drug costs were estimated from the perspective of the Colombian General Social Security Health System. Clinical scenarios included mild or moderate bleeding, severe bleeding, minor surgery, and major surgery. Costs were calculated according to patient body weight, dosing regimen, and number of doses, using locally applicable unit prices and dosing ranges derived from product labels and clinical practice. Outcomes included total pharmacological cost per patient and incremental cost differences between rFVIIa and pd-FVII across scenarios.
RESULTS: In scenarios involving severe bleeding or major surgery, rFVIIa was associated with lower pharmacological costs compared with pd-FVII in patients weighing more than 18 kg under single-dose regimens and more than 9-10 Kg when two or more doses were required. For mild or moderate bleeding and minor surgery, cost advantages for rFVIIa were observed primarily in higher-weight patients (>30 Kg) when single doses were used; however, the body weight threshold at which rFVIIa became cost-saving decreased as dosing frequency increased.
CONCLUSIONS: From the Colombian payer perspective, rFVIIa demonstrates lower pharmacological costs than pd-FVII in patients with higher body weight, multiple-dose regimens, and in the management of severe bleeding or major surgical procedures.
METHODS: A cost comparison analysis was conducted following methodological recommendations of the Instituto de Evaluación Tecnológica en Salud (IETS). Drug costs were estimated from the perspective of the Colombian General Social Security Health System. Clinical scenarios included mild or moderate bleeding, severe bleeding, minor surgery, and major surgery. Costs were calculated according to patient body weight, dosing regimen, and number of doses, using locally applicable unit prices and dosing ranges derived from product labels and clinical practice. Outcomes included total pharmacological cost per patient and incremental cost differences between rFVIIa and pd-FVII across scenarios.
RESULTS: In scenarios involving severe bleeding or major surgery, rFVIIa was associated with lower pharmacological costs compared with pd-FVII in patients weighing more than 18 kg under single-dose regimens and more than 9-10 Kg when two or more doses were required. For mild or moderate bleeding and minor surgery, cost advantages for rFVIIa were observed primarily in higher-weight patients (>30 Kg) when single doses were used; however, the body weight threshold at which rFVIIa became cost-saving decreased as dosing frequency increased.
CONCLUSIONS: From the Colombian payer perspective, rFVIIa demonstrates lower pharmacological costs than pd-FVII in patients with higher body weight, multiple-dose regimens, and in the management of severe bleeding or major surgical procedures.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE165
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Rare & Orphan Diseases